Under the terms of the Agreement, The University of Texas, MD Anderson
Cancer Center, has granted the Company a first option to obtain an
exclusive worldwide royalty-bearing commercial license to commercialize
any discovered biomarkers or pathways identified by the Company.

For the third time in four years, The University of Texas M. D. Anderson
Cancer Center is ranked the nation's top cancer hospital in U.S. News
and World Report's "America's Best Hospitals" survey, published in the
magazine's July 28 issue.

Stephen D. Barnhill, M.D., Chairman and Chief Executive Officer of
Direct Wireless Communications stated, "This is a tremendous opportunity
for our Company to demonstrate our ability to identify new biomarkers
and pathways in cancer and then commercialize our discovery." Dr.
Barnhill continued, "we look forward to working with the Physicians and
Clinical Scientists at MD Anderson Cancer Center on this very exciting
project."

Dr. Herbert Fritsche, Professor and Chief of Clinical Chemistry, at MD
Anderson Cancer Center said, "This collaboration with Health Discovery
Corporation will give us access to new bioinformatics tools for data
analysis that will lead to discovery in leukemia. We hope to use these
bioinformatics tools to develop new diagnostic approaches for leukemia
and improve the clinical management of these patients."

Leukemia is a type of cancer that originates in the bone marrow. The
accumulation of malignant cells interferes with the body's production of
healthy blood cells and makes the body unable to protect itself against
infections. According to the National Cancer Institute (NCI), over
30,000 new cases of leukemia are diagnosed each year in the United
States alone.

Direct Wireless Communications, Inc. is in the process of changing its
name to Health Discovery Corporation. Health Discovery Corporation was
established in September 2003 to become the world's first fully
integrated biomarker Discovery Company. The Company will provide
pharmaceutical and diagnostic companies with all aspects of "first
phase" diagnostic and drug discovery.

This news release contains "forward-looking statements" within the
meaning of Section 27a of the Securities Acts of 1933 and Section 21E of
the Securities Exchange Act of 1934. Although the Company believes that
the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove
correct.

DISCLAIMER: the above news article is believed accurate but not guaranteed, and is based on news supplied by the company or organization mentioned and/or quoted in the story. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news item are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope/Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. Reproduction of this news article in any form requires written authorization  use of the raw text version of the news has no restrictions other than you may not post our news on a website which offers either PR or newswire services, or Internet Promotion services.. You may freely link to this article. eNewsChannels (www.eNewsChannels.com) is a unit of Neotrope®. Keyword marketing technology by DotComMojo, a unit of Neotrope. NEWSWIRE TERMS OF USE